Glybovin 5 Tablet contains Glibenclamide 5 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Glybovin 5 is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled by lifestyle modifications alone. The medication is typically administered once or twice daily, with dosage individualized based on patient response and glycemic targets. Caution is advised in patients with hepatic or renal impairment, as altered metabolism and excretion may increase the risk of hypoglycemia. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances such as nausea and epigastric discomfort. Patients should be educated on recognizing and managing hypoglycemic episodes and advised to maintain consistent meal patterns while on therapy. Glybovin 5 is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended to optimize therapy and minimize risks. This medication should be used under strict medical supervision to ensure safety and efficacy in diabetes management.